dbo:abstract
|
- Rufinamid (Handelsname Inovelon®) ist ein krampfunterdrückender Arzneistoff, der in der Behandlung des Lennox-Gastaut-Syndroms, einer besonders schwer verlaufenden Form der Epilepsie, eingesetzt wird. Es ist nur zur Zusatztherapie ab dem vierten Lebensjahr zugelassen. (de)
- Rufinamida (Inovelon ®) es un agente anticonvulsivante, especialmente indicado en el síndrome de Lennox-Gastaut, una variedad de epilepsia. Es una terapia adicional autorizada desde el cuarto año de vida. (es)
- Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai. Rufinamide was approved by the US Food and Drug Administration (FDA) in November 2008, as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children four years and older and adults. Its official FDA-approved labeling does not mention use in the treatment of partial seizures inasmuch as clinical trials submitted to the FDA were marginal. However, several recent clinical trials suggest that the drug has efficacy for partial seizures It is marketed under the brand name Banzel. It is also marketed in the European Union under the brand name Inovelon. It is available as a generic medication. The mechanism of action of rufinamide is not fully understood. There is some evidence that rufinamide can modulate the gating of voltage-gated sodium channels, a common target for antiepileptic drugs. A recent study indicates subtle effects on the voltage-dependence of gating and the time course of inactivation in some sodium channel isoforms that could reduce neuronal excitability. However, this action cannot explain the unique spectrum of activity of rufinamide. (en)
- ルフィナミド(Rufinamide)は抗てんかん薬の一つである。レノックス・ガストー症候群の治療について他の抗てんかん薬との併用で用いる旨が承認されている。他の痙攣性発作について承認されている国もある。商品名イノベロン。 ルフィナミドは2008年11月に米国FDAに承認された。日本では2013年3月に承認された。4歳以上の小児および成人に使用できる。2015年2月、米国で1歳〜3歳の小児に対して追加承認された。 (ja)
- La rufinamide è un farmaco anticonvulsante utilizzato in combinazione con altri farmaci antiepilettici per trattare una rara forma di epilessia chiamata sindrome di Lennox-Gastaut. Lo sviluppo iniziale è stato portato avanti dalla Novartis mentre adesso è prodotto, ulteriormente sviluppato e commercializzato da Eisai. L'Agenzia europea per i medicinali (EMEA) ha approvato la sua immissione in commercio nell'Unione europea il 16 gennaio 2007. (it)
|
dbo:alternativeName
| |
dbo:bioavailability
| |
dbo:casNumber
| |
dbo:chEMBL
| |
dbo:fdaUniiCode
| |
dbo:kegg
| |
dbo:medlinePlus
| |
dbo:pubchem
| |
dbo:thumbnail
| |
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 6892 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:atcPrefix
| |
dbp:atcSuffix
| |
dbp:bioavailability
| |
dbp:c
| |
dbp:casNumber
| |
dbp:chembl
| |
dbp:chemspiderid
| |
dbp:dailymedid
| |
dbp:eliminationHalfLife
| |
dbp:excretion
| |
dbp:f
| |
dbp:h
| |
dbp:iupacName
| |
dbp:iupharLigand
| |
dbp:kegg
| |
dbp:legalStatus
| |
dbp:legalUk
| |
dbp:legalUs
| |
dbp:licenceEu
| |
dbp:licenceUs
| |
dbp:medlineplus
| |
dbp:metabolism
|
- Carboxylesterase-mediated hydrolysis (en)
|
dbp:metabolites
| |
dbp:n
| |
dbp:o
| |
dbp:pregnancyAu
| |
dbp:proteinBound
| |
dbp:pubchem
| |
dbp:routesOfAdministration
| |
dbp:smiles
| |
dbp:stdinchi
| |
dbp:stdinchikey
|
- POGQSBRIGCQNEG-UHFFFAOYSA-N (en)
|
dbp:tradename
| |
dbp:unii
| |
dbp:verifiedfields
| |
dbp:verifiedrevid
| |
dbp:watchedfields
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
gold:hypernym
| |
rdf:type
| |
rdfs:comment
|
- Rufinamid (Handelsname Inovelon®) ist ein krampfunterdrückender Arzneistoff, der in der Behandlung des Lennox-Gastaut-Syndroms, einer besonders schwer verlaufenden Form der Epilepsie, eingesetzt wird. Es ist nur zur Zusatztherapie ab dem vierten Lebensjahr zugelassen. (de)
- Rufinamida (Inovelon ®) es un agente anticonvulsivante, especialmente indicado en el síndrome de Lennox-Gastaut, una variedad de epilepsia. Es una terapia adicional autorizada desde el cuarto año de vida. (es)
- ルフィナミド(Rufinamide)は抗てんかん薬の一つである。レノックス・ガストー症候群の治療について他の抗てんかん薬との併用で用いる旨が承認されている。他の痙攣性発作について承認されている国もある。商品名イノベロン。 ルフィナミドは2008年11月に米国FDAに承認された。日本では2013年3月に承認された。4歳以上の小児および成人に使用できる。2015年2月、米国で1歳〜3歳の小児に対して追加承認された。 (ja)
- La rufinamide è un farmaco anticonvulsante utilizzato in combinazione con altri farmaci antiepilettici per trattare una rara forma di epilessia chiamata sindrome di Lennox-Gastaut. Lo sviluppo iniziale è stato portato avanti dalla Novartis mentre adesso è prodotto, ulteriormente sviluppato e commercializzato da Eisai. L'Agenzia europea per i medicinali (EMEA) ha approvato la sua immissione in commercio nell'Unione europea il 16 gennaio 2007. (it)
- Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai. (en)
|
rdfs:label
|
- Rufinamid (de)
- Rufinamida (es)
- Rufinamide (it)
- ルフィナミド (ja)
- Rufinamide (en)
- Rufinamida (pt)
|
owl:differentFrom
| |
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is owl:differentFrom
of | |
is foaf:primaryTopic
of | |